UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2018 (February 21, 2018)
Blue Sphere Corporation
(Exact name of registrant as specified in its charter)
Nevada | 000-55127 | 98-0550257 | ||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
301 McCullough Drive, 4th Floor, Charlotte, North Carolina 28262 |
(Address of principal executive offices) (Zip Code) |
704-909-2806 |
(Registrant’s telephone number, including area code) |
|
(Former Name or Former Address, if Changed since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
☒ Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report, all references to the terms “we”, “us”, “our”, “Blue Sphere” or the “Company” refer to Blue Sphere Corporation and its direct and indirect wholly-owned subsidiaries, unless the context clearly requires otherwise.
Item 1.01
Entry into a Material Definitive Agreement
On February 21, 2018, the Company and JMJ Financial (the “Investor”) entered into a Loan Extension, Additional Investment & Conversion Agreement (the “Agreement”).
The Agreement concerns that certain Securities Purchase Agreement Document SPA-10212016, dated as of October 24, 2016, between the Company and the Investor (as amended, the “SPA”), pursuant to which the Company delivered to the Investor (a) a Promissory Note (as amended, the “Note”); (b) six (6) warrants, dated December 20, 2016, February 14, 2017, March 14, 2017, April 13, 2017, May 11, 2017, and June 7, 2017 (as amended, the “Warrants”), to purchase shares of the Company’s common stock, $0.001 per share (“Common Stock”); and (c) an agreement to issue, by a specified date, restricted shares of Common Stock equal to twenty-five percent (25%) of the Note principal paid to the Company (the “Origination Shares”). By letter agreement or amendment, on ten (10) separate occasions (the “Amendments”), (a) the Company and the Investor agreed to amend certain terms and extend certain milestone dates contained in the SPA, the Note and the Warrants, with the last such Amendment extending the maturity date of the Note, the date the Origination Shares were issuable, the date of the pricing reset on the Origination Shares and the date to receive conditional approval from The NASDAQ Capital Market or NYSE-MKT to November 22, 2017; and (b) the Investor agreed to conditionally waive any default in connection with the original dates, but not the damages, fees, penalties, liquidated damages, or other amounts or remedies otherwise resulting from such a default, under the SPA, the Note and the Warrants, with the waiver conditioned on the Company not triggering an event of default at any time subsequent to such Amendment. One of the Amendments increased the principal sum (inclusive of an “origination fee”) of the Note to USD $2,106,000, and increased the amount of consideration payable under the Note to USD $2,000,000. The Investor paid all USD $2,000,000 of consideration to the Company under the Note, and on June 30, 2017, the Company repaid USD $1,000,000 of the outstanding balance due under the Note.
On February 13, 2018, the Company issued a short-term Promissory Note #3 to the Investor (the “Feb 2018 Note”) in exchange for an investment of USD $250,000. The maturity date of the Feb 2018 Note was ten (10) calendar days from the date thereof, or February 23, 2018. The Feb 2018 Note incorporated the terms of the Note, and was entered into in contemplation of the parties entering into the Agreement. As detailed below, the Feb 2018 Note is now null and void.
The Agreement further amends the SPA, the Note and the Warrants, and provides for additional investments to be made by the Investor. Specifically, the Agreement provides that:
(a) | the principal sum of the Note was increased to USD $4,212,000 and the amount of consideration payable under the Note was increased to USD $4,000,000; |
(b) | the Investor invested an additional USD $1,000,000 under the Note, of which USD $750,000 was wired to the Company, and USD $250,000 was funded by rolling over and applying the principal balance of the Feb 2018 Note to the Note; |
(c) | the Feb 2018 Note was deemed null and void; |
(d) | the Investor will invest at least USD $1,000,000 and up to USD $5,000,000 under a public offering of the Company’s securities to raise gross proceeds to the Company of at least USD $5,000,000 (the “Public Offering”) occurring contemporaneously with an up-listing of the Common Stock on The Nasdaq Capital Market or the NYSE-MKT (the “Up-list”); |
(e) | the Investor extended the maturity date of the Note, the date the Origination Shares are issuable under the SPA, the date of the pricing reset on the Origination Shares and the date to receive conditional approval for the Up-list from The NASDAQ Capital Market or the NYSE-MKT, in all cases, to June 30, 2018; |
(f) | the Investor provided a conditional waiver of any default in connection with the original dates, but not the damages, fees, penalties, liquidated damages, or other amounts or remedies otherwise resulting from such a default, under the SPA, the Note and the Warrants, with such waiver conditioned on the Company not triggering an event of default at any time subsequent to the Agreement; |
(g) | if, by June 30, 2018, a Public Offering closes and the Company successfully contemporaneously Up-lists, the Investor will accept shares of Common Stock in lieu of cash to (i) settle estimated liquidated damages which have occurred under the Note, the SPA and the Warrants due to events of default therein, (ii) convert the outstanding principal balance of the Note (which will then be deemed terminated), (iii) exercise the Warrants in full, and (iv) secure Investor’s agreement to lock-up 50% of the shares of Common Stock acquired in connection with the Agreement for three (3) months following the closing of a Public Offering; and |
(h) | subject to specified exceptions, the Company will agree not to issue or sell, or grant any option, warrant or other right to purchase or acquire, shares of Common Stock, for a period of one (1) year after the closing of the Public Offering and completed Up-list. |
In addition to the foregoing terms, the Agreement includes a beneficial ownership limitation, providing that the Company will not issue to the Investor any number of shares issuable upon a conversion under the Agreement that would result in the Investor owning more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such issuance. At the Investor’s election, the Company will create a series of preferred stock convertible into shares of Common Stock, to be issued in lieu of any shares of Common Stock converted under the Agreement that were not issuable due to said beneficial ownership limitation.
The foregoing descriptions of the Agreement and the Feb 2018 Note are not complete and are qualified in their entirety by reference to the full texts of the Agreement and the Feb 2018 Note, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report, and are incorporated by reference herein.
Except as modified by the Agreement, all other terms of the SPA, the Note and the Warrants remain in full force and effect. The foregoing descriptions of the SPA, the Note, the Warrants and the Amendments are not complete and are qualified in their entirety by reference to the full text of the SPA, the Note, the Warrants and the Amendments, copies of which are filed as Exhibits 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14 and 10.15, respectively (with the Amendments filed as Exhibits 10.6 through 10.15 in chronological order), to this Current Report, and are incorporated by reference herein.
The Company is providing this report in accordance with Rule 135c under the Securities Act of 1933, as amended (the “Securities Act”), and the notice contained herein does not constitute an offer to sell the Company’s securities, and is not a solicitation for an offer to purchase the Company’s securities. The securities offered have not been registered under the Securities Act, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
Reference is made to the disclosure set forth under Item 1.01 above, which disclosure is incorporated herein by reference.
Item 3.02
Unregistered Sales of Equity Securities
Reference is made to the disclosure set forth under Item 1.01 above, which disclosure is incorporated herein by reference.
The Company has sold the securities in a private transaction in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder since, among other things, the above transaction did not involve a public offering. Additionally, the Company relied on similar exemptions under applicable state laws. The Holders had access to information about the Company and their investments, took the securities for investment and not resale, and the Company took appropriate measures to restrict the transfer of the securities. Upon issuance, the resale of the securities will not be registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Item 9.01
Financial Statements and Exhibits.
The following exhibits are furnished as part of this Current Report on Form 8-K:
(d) Exhibits.
No. | Agreement | Note |
10.1 | Loan Extension, Additional Investment & Conversion Agreement, dated February 21, 2018, between Blue Sphere Corporation and JMJ Financial. | (1) |
10.2 | Promissory Note #3, dated February 13, 2018, issued by Blue Sphere Corporation to JMJ Financial. | (1) |
10.3 | Form of Securities Purchase Agreement Document SPA-10212016, dated as of October 24, 2016, between Blue Sphere Corporation and JMJ Financial. | (2) |
10.4 | Form of Promissory Note, dated October 25, 2016, between Blue Sphere Corporation and JMJ Financial. | (2) |
10.5 | Form of Common Stock Purchase Warrants issued by Blue Sphere Corporation to JMJ Financial. | (2) |
10.6 | Letter Agreement, dated March 1, 2017, between JMJ Financial and Blue Sphere Corporation. | (3) |
10.7 | Amendment #2 to the Securities Purchase Agreement and to the $1,053,000 Promissory Note, dated March 14, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (4) |
10.8 | Amendment #3 to the Securities Purchase Agreement and to the $1,579,500 Promissory Note, dated April 13, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (5) |
10.9 | Amendment #4 to the Securities Purchase Agreement, the $1,579,500 Promissory Note, and the Common Stock Purchase Warrants, dated April 28, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (5) |
10.10 | Amendment #5 to the Securities Purchase Agreement and to the $1,579,500 Promissory Note, dated May 11, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (5) |
10.11 | Amendment #6 to the Securities Purchase Agreement, the $2,106,000 Promissory Note, and the Common Stock Purchase Warrants, dated May 18, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (6) |
10.12 | Amendment #7 to the Securities Purchase Agreement, the $2,106,000 Promissory Note, and the Common Stock Purchase Warrants, dated June 6, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (7) |
10.13 | Amendment #8 to the Securities Purchase Agreement, the $2,106,000 Promissory Note, and the Common Stock Purchase Warrants, dated June 6, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (8) |
10.14 | Amendment #9 to the Securities Purchase Agreement, to the Promissory Note, and to the Common Stock Purchase Warrants, dated September 21, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (9) |
10.15 | Amendment #10 to the Securities Purchase Agreement, to the Promissory Note, and to the Common Stock Purchase Warrants, dated November 14, 2017, by and between Blue Sphere Corporation and JMJ Financial. | (9) |
(1) | Filed herewith. |
(2) | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on October 31, 2016. |
(3) | Incorporated by reference to our Amendment No. 2 to Registration Statement on Form S-1/A (File No. 333-215110) filed with the SEC on March 7, 2017. |
(4) | Incorporated by reference to our Current Report on Form 8-K filed with the SEC on March 20, 2017. |
(5) | Incorporated by reference to our Quarterly Report on Form 10-Q filed with the SEC on May 15, 2017. |
(6) | Incorporated by reference to our Amendment No. 4 to Registration Statement on Form S-1/A (File No. 333-215110) filed with the SEC on May 30, 2017. |
(7) | Incorporated by reference to our Registration Statement on Form S-1 (File No. 333-218692) filed with the SEC on June 13, 2017. |
(8) | Incorporated by reference to our Amendment No. 5 to Registration Statement on Form S-1/A (File No. 333-215110) filed with the SEC on July 24, 2017. |
(9) | Incorporated by reference to our Quarterly Report on Form 10-Q filed with the SEC on November 20, 2017. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Blue Sphere Corporation | ||
Dated: February 27, 2018 | By: | /s/ Shlomi Palas |
Shlomi Palas | ||
President and Chief Executive Officer |
Exhibit 10.1
LOAN EXTENSION, ADDITIONAL INVESTMENT & CONVERSION AGREEMENT
Addendum to the Transaction Documents Dated October 24, 2016
This Loan Extension, Additional Investment & Conversion Agreement, dated February 21, 2018 (this “ Agreement ”), is by and between Blue Sphere Corporation, a Nevada corporation (the “ Issuer ”) and JMJ Financial (the “ Investor ”) (referred to collectively herein as the “ Parties ”).
WHEREAS, the Issuer and the Investor entered into a Securities Purchase Agreement Document SPA-10212016 (as amended, the “ SPA ”) dated as of October 24, 2016, pursuant to which the Issuer issued to the Investor a Promissory Note (as amended, the “ Note ”), a Warrant, and Origination Shares (all capitalized terms not otherwise defined herein shall have the meanings given such terms in the SPA);
WHEREAS, the Issuer issued additional common stock purchase warrants to the Investor on December 20, 2016, February 14, 2017, March 14, 2017, April 13, 2017, May 11, 2017, and June 7, 2017 (such warrants, plus the Warrant, plus any additional warrants the Issuer may be required to issue to the Investor in the future under the SPA, all as previously amended, the “ Warrants ”);
WHEREAS, by letter agreement or amendment, on at least ten separate occasions (the “ Amendments ”), (i) the Issuer and the Investor agreed to amend certain terms and extend certain milestone dates contained in the SPA, Note and the Warrants, with the last such Amendment extending the maturity date of the Note, the date the Origination Shares were issuable, the date of the pricing reset on the Origination Shares and the date to receive conditional approval from The NASDAQ Capital Market to November 22, 2017; and (ii) the Investor agreed to conditionally waive any default in connection with the original dates, but not the damages, fees, penalties, liquidated damages, or other amounts or remedies otherwise resulting from such a default under the SPA, Note and the Warrants, and with the waiver conditioned on the Issuer not triggering an event of default at any time subsequent to such Amendment;
WHEREAS, one of the Amendments increased the Principal Sum of the Note to $2,106,000 and increased the amount of Consideration payable under the Note to $2,000,000;
WHEREAS, the Investor had paid all $2,000,000 of Consideration to the Issuer under the Note;
WHEREAS, on June 30, 2017, the Issuer repaid $1,000,000 of the outstanding balance under the Note;
WHEREAS, the Issuer requests that the Investor agree (i) to increase the Principal Sum of the Note to $4,212,000 and increase the amount of Consideration payable under the Note to $4,000,000, and (ii) to invest an additional $1,000,000 into the Issuer under the Note at this time, which would leave an additional $1,000,000 of Consideration available for payment under the Note at a future date if necessary;
WHEREAS, the Issuer further requests that the Investor invest an additional $1,000,000 into the Issuer under a public offering of the Issuer’s securities to raise gross proceeds to the Issuer of at least $5,000,000 (the “ Public Offering ”), provided that such Public Offering may be for less upon the mutual agreement of the Issuer and the Investor and further provided that such Public Offering occurs in conjunction with an uplisting of the Issuer's securities to The Nasdaq Capital Market or NYSE-MKT;
WHEREAS, the Issuer has requested several extensions on the Note due to delays in the Public Offering; and
WHEREAS, in order to improve the likelihood of success of the Public Offering and the uplisting of the Issuer's securities to The Nasdaq Capital Market or NYSE-MKT, the Issuer requests that the Investor accept shares of stock instead of cash to settle all of the Issuer’s obligations to the Investor.
1 |
NOW, THEREFORE, the Issuer and the Investor agree as follows:
1.
Additional Investment and Commitment .
A.
$1,000,000 Investment into the Current Note Structure. Within five business days after the date of this Agreement, the Investor shall invest an additional $1,000,000 into the Issuer under the Note by paying $750,000 cash to the Issuer and by rolling over and applying to the Note the $250,000 Principal Sum due to the Investor under the $250,000 Note that was funded by the Investor by $250,000 wire transfer and was issued to the Investor on February 13, 2018, after which time the $250,000 Note shall be null and void.
B.
$1,000,000 Investment into the Public Offering. The Investor commits to invest at least $1 million in a Public Offering that occurs contemporaneously with an uplisting of the Issuer's securities to The Nasdaq Capital Market or NYSE-MKT (the Investor shall not commit to participating in any offering other than as per the terms of this Agreement and in conjunction with an uplisting). The Investor shall have the right, at its election, to invest up to $5 million in the Public Offering, and up to $5 million in each of the Issuer's subsequent financings during the two- year period after the Public Offering, on the same terms as the best terms, as determined by the Investor, provided to any investor in the Public Offering or in any such subsequent financing.
2.
Extensions .
A.
Extension of Maturity Date. In the sentence in the Note (as previously amended) that states “The Maturity Date is the earlier of November 22, 2017 or the third business day after the closing of the Public Offering,” the date of November 22, 2017 shall be replaced with the date of June 30, 2018.
B.
Extension of Origination Shares Dates. The references to the date of November 22, 2017 in Sections 1.3.1 and 1.3.2 of the SPA (as previously amended) shall be replaced with the date of June 30, 2018.
C.
Extension of Nasdaq Approval Date. Section 6(xxiii) of the Note and Section 1.11(xxiii) of the Warrants shall hereinafter be deleted and replaced with the following text: “(xxiii) the Issuer fails to obtain from Nasdaq or NYSE or another exchange mutually agreed upon by the Issuer and the Investor by June 30, 2018 and conditional approval of the listing of the Issuer’s common stock on The Nasdaq Capital Market or NYSE-MKT or another exchange mutually agreed upon by the issuer and the Investor subject only to completion of the Public Offering pursuant to the Registration Statement and to the Issuer’s common stock maintaining the minimum price requirements prior to up-listing;”.
D.
Conditional Waiver of Default. The Investor conditionally waives the defaults for the Issuer's failure to meet the original and previously amended Maturity Dates of the Note and delivery dates for the Origination Shares, but the Investor does not waive any damages, fees, penalties, liquidated damages, or other amounts or remedies otherwise resulting from such defaults (which damages, fees, penalties, liquidated damages, or other amounts or remedies the Investor may choose in the future to assess, apply or pursue in its sole discretion) and the Investor's conditional waiver is conditioned on the Issuer's not being in default of and not breaching any term of the Note or the SPA or any other Transaction Documents at any time subsequent to the date of this Agreement (if the Issuer triggers an event of default or breaches any term of the Note, the SPA, or the Transaction Documents at any time subsequent to the date of this Agreement, the Investor may issue a notice of default for the Issuer's failure to meet the original Maturity Date of the Note and delivery date of the Origination Shares).
2 |
3.
Conversion to Equity Upon Up-listing . Provided that (i) the Issuer closes on the Public Offering and contemporaneously uplists its shares of common stock on The Nasdaq Capital Market or NYSE-MKT, or contemporaneously uplists to another exchange mutually agreed upon by the Issuer and the Investor, by June 30, 2018, and (ii) no additional event of default or breach of the Transaction Documents occurs between the date of this Agreement and the close of the Public Offering, the Issuer may terminate the Note and satisfy all of the Issuer's obligations to the Investor by payment of stock as follows:
A.
No Cash Payment. The Issuer shall not pay to the Investor any part of the Note balance in cash at the closing of the Public Offering. In consideration of the Investor agreeing to forego payment in cash, the Issuer agrees to pay to the Investor $250,000 in common stock of the Issuer (" Conversion Shares ").
B.
Repayment of Note Principal Sum in Stock. The Issuer shall pay the Principal Sum of the Note (Consideration paid plus OID (excluding the extension fees and damages on the Note, which will be paid in stock under 3.D. and 3.E. below)) in shares of common stock of the Issuer (" Note Balance Shares ").
C.
Warrants. In order to clean up and simplify the Issuer’s capital structure, all of the Warrants shall be exchanged for an identical dollar amount of shares of common stock of the Issuer (" Warrant Shares ").
D.
Extensions. The Issuer agrees to pay to the Investor $750,000 in shares of common stock of the Issuer (" Extension Shares ") as fees for the several extensions the Investor has provided under the SPA, the Note, and the Warrants. The Investor agrees that it will reduce the dollar amount of the Extension Shares by $500,000 to $250,000 if the Issuer lists its common stock on The Nasdaq Capital Market or NYSE-MKT or another exchange mutually agreed upon by the Issuer and the Investor by March 31, 2018.
E.
Damages. As negotiated by the Issuer and as a gesture of good faith by the Investor, the Investor agrees to reduce the damages otherwise payable under the Note by approximately $500,000 in exchange for a settlement payment of $3,000,000 that the Issuer agrees to pay in shares of common stock of the Issuer (" Settlement Shares ").
F.
Lockup Fee. The Issuer agrees to pay the Investor a lockup fee of $250,000 payable in shares of common stock of the Issuer (" Lockup Shares ") as consideration for the Investor entering into a lockup agreement on up to 50% of the Investor Shares (defined below), not to exceed three months, that will be effective upon closing of the Public Offering and that will prohibit the Investor from selling more than 50% of the Investor Shares at a price lower than the lesser of (i) the price per share of the Issuer's common stock in the Public Offering, or (ii) the closing price of the Issuer's common stock on the date of this Agreement. The Investor shall not be subject to a lockup on any shares that the Investor acquires in the Public Offering.
G.
Share Delivery and Pricing.
1 Pricing in the Event of Up-listing with a Public Offering. The number of Conversion Shares, Note Balance Shares, Warrant Shares, Extension Shares, Settlement Shares, and Lockup Shares (collectively, " Investor Shares ") deliverable to the Investor, and the time for delivery of the Investor Shares, shall be determined in accordance with the pricing formula and delivery deadlines set forth in Section 1.3 of the SPA as if such Investor Shares were Origination Shares. All Origination Shares remain due and payable as set forth in the SPA and, for the avoidance of doubt, all of the shares deliverable to the Investor under this Agreement are in addition to the Origination Shares due to the Investor under the SPA.
3 |
2 Pricing in the Event of Up-listing without a Public Offering. In the event that Issuer does not complete the Public Offering, but instead uses an alternative method to list its shares of common stock on The Nasdaq Capital Market or NYSE-MKT or another exchange mutually agreed upon by the Issuer and the Investor, and if the Issuer and the Investor agree to the Issuer settling its obligations to the Investor by delivering Investor Shares to the Investor, then on the fifth (5th) trading day after the day the Issuer's shares of common stock begin trading on The Nasdaq Capital Market or NYSE-MKT or another exchange mutually agreed upon by the Issuer and the Investor (the " Listing Date ") the Issuer shall deliver to the Investor such number of duly and validly issued, fully paid and non-assessable Investor Shares as equals the dollar amount of the Investor Shares divided by the lowest of (i) the lowest daily closing price of the Issuer’s common stock during the ten days prior to delivery of the Investor Shares or during the ten days prior to the date of this Agreement (in each case subject to adjustment for stock splits), (ii) 80% of the closing price of the common stock on the Listing Date, (iii) 80% of the effective offering price per share of common stock of the Issuer in any private placement or issuance of securities by the Issuer after the date of this Agreement and prior to the Listing Date (if applicable), (iv) 80% of the unit offering price in any private placement or issuance of securities by the Issuer after the date of this Agreement and prior to the Listing Date (if applicable), or (v) $1.60 (subject to adjustment for stock splits) (such lowest price of (i), (ii), (iii), (iv), or (v) is hereafter referred to as the " Lowest Price "). It is the Issuer’s and the Investor’s expectation that the issuance date of the Investor Shares dates back to the dates of the Investor's payment of Consideration under the Note, in proportion to the amount of each payment, for purposes of Rule 144 under the Securities Act of 1933, as amended.
4.
Investor Shares Beneficial Ownership Limitation . Unless otherwise agreed by both Parties, at no time will the Issuer issue to the Investor such number of Investor Shares that would result in the Investor owning more than 9.99% of the number of shares of common stock outstanding of the Issuer immediately after giving effect to the issuance of the Investor Shares (the " Beneficial Ownership Limitation "). In the event that the number of Investor Shares deliverable to the Investor would cause the Investor to exceed the Beneficial Ownership Limitation, the Issuer shall deliver to the Investor such lesser number of Investor Shares the Investor requests that would result in the Investor owning less than the Beneficial Ownership Limitation and the Issuer shall deliver to the Investor the remaining number of Investor Shares at such time as the Investor notifies the Issuer that delivery of such remaining Investor Shares would not cause the Investor to exceed the Beneficial Ownership Limitation.
5.
Investor's Election for Preferred Stock . At the Investor's election at any time the Issuer shall create, within five (5) business days after the Investor's election, a series of convertible preferred stock out of the Issuer’s existing authorized shares of preferred stock to address the Beneficial Ownership Limitation on Investor Shares. The Issuer shall cooperate with the Investor in drafting the terms of the series of convertible preferred stock, and in exchanging the Investor Shares for shares of the newly created series of convertible preferred stock, so as to accomplish the objectives of this paragraph. The Issuer shall reserve for this purpose, until such time as the Investor's right to elect expires, 10,000,000 shares out of the Issuer’s 500,000,000 authorized and undesignated shares of the Issuer's $0.001 par value preferred stock.
4 |
6.
Note Amount . The Principal Sum of the Note, as previously amended, is hereby increased from $2,106,000 to $4,212,000 and the Consideration is increased to $4,000,000. The first five sentences of the second paragraph of the Note are hereby amended and replaced with the following:
“The Principal Sum is up to $4,212,000 (four million two hundred twelve thousand) plus accrued and unpaid interest and any other fees. The Consideration is $4,000,000 (four million) payable by wire. The Investor shall pay $750,000 of Consideration in accordance with the attached Funding Schedule in its sole election. The Investor may pay up to an additional $3,250,000 of Consideration to the Issuer in such amounts and at such dates as the Investor may choose, however, the Issuer has the right to reject any of those payments within 24 hours of receipt of rejected payments. The Principal Sum due to the Investor shall be based on the Consideration actually paid by Investor (plus an approximate 5% Original Issue Discount that is based on the Consideration actually paid by the Investor as well as any other interest or fees) such that the Issuer is only required to repay the amount funded and the Issuer is not required to repay any unfunded portion of this Note.”
7.
SPA Amendments . The reference to a Note aggregate principal amount of $2,106,000 contained in Section 1.1 of the SPA, as previously amended, shall be amended to refer to a Note aggregate principal amount of $4,212,000. The reference to a total Consideration amount of $2,000,000 contained in Section 1.4 of the SPA shall be amended to refer to a total Consideration amount of $4,000,000. All references to the SPA or the Note in any of the Transaction Documents, including any Warrants issued after the date of the SPA, shall refer to the SPA, as amended, and to the Note, as amended.
8.
One Year Prohibition on Issuances of Securities . For a period of one year after the later of the closing of the Public Offering, the Listing Date, or the closing of a private placement of the Issuer's securities (the " Starting Date "), without the express written consent of the Investor, the Issuer shall not issue or sell common stock, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any common stock (including pursuant to the terms of any outstanding securities issued prior to the Starting Date (including, but not limited to, warrants, convertible notes, or other agreements)) or any security entitling the holder thereof to acquire common stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive common stock at an effective price per share less than the greatest of (i) the Lowest Price (as defined Section 3.F.2 above), (ii) the common stock offering price in the Public Offering or private placement (as may be applicable), (iii) the unit offering price in the Public Offering or private placement (as may be applicable), and (iv) the exercise price of any warrants issued in the Public Offering or private placement (as may be applicable). The foregoing prohibition on issuances of securities shall not apply to any issuances of securities to any project partner or to any funding directly related to project financing, or to any grant or issuance of shares of the Issuer’s common stock or options to purchase shares of the Issuer’s common stock pursuant to the Issuer’s 2016 and 2018 Stock Incentive Plan, Non-Employee Directors Compensation Plan or service or employment agreements outstanding as of the date of this Agreement.
9.
TA Letters . The Issuer agrees that the terms of the irrevocable instruction letter dated October 24, 2016 in which the Issuer irrevocably authorized and instructed ClearTrust, LLC to issue shares of common stock of the Issuer to the Investor without any further action or confirmation by the Issuer upon ClearTrust's receipt from the Investor of a Conversion Notice or Exercise Notice shall apply to the Note as amended and shall apply to all warrants the Issuer has issued or will issue to the Investor pursuant to the terms of the SPA as amended. In addition, the Issuer agrees that the terms of the irrevocable instruction letter dated October 24, 2016 in which the Issuer irrevocably authorized and instructed ClearTrust, LLC to issue shares of common stock of the Issuer to the Investor without any further action or confirmation by the Issuer upon ClearTrust's receipt from the Investor of a request for issuance of Origination Shares pursuant to the Issuer's obligations under the SPA shall apply to all requests for issuance of Origination Shares pursuant to the Issuer's obligations under the SPA as amended, and also shall apply to the Issuer's obligation to issue Investor Shares, such that the share reserve also may be used for requests from the Investor of Investor Shares and ClearTrust hereby is irrevocably authorized and instructed to issue Investor Shares to the Investor upon ClearTrust's receipt from the Investor of a request for Investor Shares. If ClearTrust requires the Issuer and/or the Investor to deliver to ClearTrust new irrevocable instruction letters to give effect to the terms of this paragraph, the Issuer agrees that it will cooperate in good faith with the Investor in drafting and executing the new irrevocable instruction letters and any supporting documents required by ClearTrust and the Issuer shall promptly deliver the new irrevocable instruction letters to ClearTrust.
5 |
10.
All Other Terms Remain in Full Force and Effect . All other terms and conditions of the Transaction Documents, including all Warrants and all amendments to such Transaction Documents, remain in full force and effect. The terms of this Agreement do not terminate or relieve the Issuer of its obligation to perform or forbear from performing under any term of the Transaction Documents that is meant to survive after the closing of the Public Offering or that does not expressly provide for its termination upon closing of the Public Offering.
* * *
Please indicate acceptance and approval of this Agreement by signing below:
/s/ Shlomi Palas | /s/ JMJ Financial | |
Shlomi Palas | JMJ Financial | |
Blue Sphere Corporation | Its Principal | |
Chief Executive Officer |
[Loan Extension, Additional Investment &Conversion Agreement Signature Page]
6 |
Exhibit 10.2
PROMISSORY NOTE #3
This Promissory Note #3, dated February 13, 2018 (this “Note #3”), is entered into by and between Blue Sphere Corporation , a Nevada corporation (the “Issuer”) and JMJ Financial, a Nevada sole proprietorship, or its assignees (the “Investor”).
WHEREAS, the Issuer and the Investor (collectively, the “Parties”) entered into Securities Purchase Agreement Document SPA-10212016, dated as of October 24, 2016 (the “Securities Purchase Agreement”), pursuant to which the Issuer issued to the Investor, among other things, a Promissory Note (“Note #2”);
WHEREAS, the Parties entered into ten amendments to the Securities Purchase Agreement and Note #2;
WHEREAS, the Parties are negotiating the terms of another amendment to the Securities Purchase Agreement and Note #2; and
WHEREAS, the Issuer requests that the Investor invest $250,000 into the Issuer under the terms of this Note #3 pending the conclusion of those negotiations.
NOW, THEREFORE, the Parties agree as follows:
1.
FOR VALUE RECEIVED, the Issuer issues this Note #3 and promises to pay to the Investor the Principal Sum and any other fees according to the terms herein. This Note #3 will become effective only upon execution by both Parties and delivery of the payment of Consideration by the Investor (the “Effective Date”).
2.
This Note #3 is not issued under the Securities Purchase Agreement and is separate and distinct from Note #2. The terms of this Note #3 do not amend or supplement the terms of the Securities Purchase Agreement or of Note #2. For clarity, no warrants or origination shares are due to the Investor under the Securities Purchase Agreement as a result of the Parties entering into this Note #3.
3.
The Principal Sum is $250,000 (two hundred fifty thousand). The Consideration is $250,000 (two hundred fifty thousand) payable by wire. The Maturity Date of this Note #3 is ten calendar days after the Effective Date of this Note #3. The Principal Sum of this Note #3, as well as any fees, shall be due and payable on the Maturity Date. The Investor may extend any Maturity Date in its sole discretion in increments of up to three calendar days at any time before or after any Maturity Date. The Maturity Date shall automatically be deemed extended unless the Investor provides notice to the Issuer that it is not or has not extended the Maturity Date, which notice the Investor may provide at any time before or after the Maturity Date.
4.
The Issuer may repay this Note #3 at any time on or before its Maturity Date. In the event the Investor submits a conversion as permitted by this Note #3, the Issuer may not repay the amount converted. The Parties may agree to apply the Principal Sum of this Note #3 as a payment of Consideration under Note #2 if and when the Parties agree to further amend the Securities Purchase Agreement and Note #2, in which case the Investor will be entitled to receive any warrants or origination shares payable to the Investor under the Securities Purchase Agreement as a result of the Investor making a payment of Consideration to the Issuer under Note #2.
5.
For simplicity, this Note #3 borrows the language of certain provisions and sections of Note #2 as follows. The language of Sections 2, 3, 5, 6(i) through 6(xvii), 7 through 14, and 16 of Note #2 are incorporated and apply to this Note #3 as if such Sections were restated here in full, except that in Section 2 the price of $0.075 shall be replaced with the price of $1.60. Any term not otherwise defined herein shall have the meaning given such term in Note #2.
* * *
Issuer: | Investor: | |
/s/ Shlomi Palas | /s/ JMJ Financial | |
Shlomi Palas | JMJ Financial | |
Blue Sphere Corporation | Its Principal | |
Chief Executive Officer | ||
Date: February 13, 2018 | Date: February 13, 2018 |